Your browser doesn't support javascript.
loading
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.
Condom, Maria; Mussetti, Alberto; Maluquer, Clara; Parody, Rocío; González-Barca, Eva; Arnan, Montserrat; Albasanz-Puig, Adaia; Pomares, Helena; Salas, Maria Queralt; Carro, Itziar; Peña, Marta; Clapes, Victòria; Baca Cano, Cristina; Oliveira Ramos, Ana Carla; Sanz-Linares, Gabriela; Moreno-González, Gabriel; Mercadal, Santiago; Boqué, Concepcion; Gudiol, Carlota; Domingo-Domènech, Eva; Sureda, Anna.
Afiliación
  • Condom M; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Mussetti A; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Maluquer C; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Parody R; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • González-Barca E; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Arnan M; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Albasanz-Puig A; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Pomares H; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Salas MQ; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Carro I; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Peña M; Universitat de Barcelona, Barcelona, Spain.
  • Clapes V; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Baca Cano C; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Oliveira Ramos AC; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), Instituto de Salud Carlos III, Madrid, Spain.
  • Sanz-Linares G; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona, Spain.
  • Moreno-González G; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Mercadal S; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Boqué C; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Gudiol C; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Domingo-Domènech E; Clinical Hematology Department, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Sureda A; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
Cancer Rep (Hoboken) ; 4(4): e1358, 2021 08.
Article en En | MEDLINE | ID: mdl-33656801
BACKGROUND: Clinical outcomes of novel coronavirus 2019 disease (COVID-19) in onco-hematological patients are unknown. When compared to non-immunocompromised patients, onco-hematological patients seem to have higher mortality rates. AIMS: We describe the characteristics and outcomes of a consecutive cohort of 24 onco-hematological patients with COVID-19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. METHODS AND RESULTS: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID-19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22-82) years. Median follow-up in survivors was 14 (9-28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D-dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID-19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID-19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (-55%) and chemotherapy sessions (-19%). A significant increase in phone visits was reported (+581%). CONCLUSION: COVID-19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antivirales / Neoplasias Hematológicas / SARS-CoV-2 / COVID-19 / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Cancer Rep (Hoboken) Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antivirales / Neoplasias Hematológicas / SARS-CoV-2 / COVID-19 / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Cancer Rep (Hoboken) Año: 2021 Tipo del documento: Article País de afiliación: España